Imidazole derivatives as a novel class of hybrid compounds with inhibitory histamine N-methyltransferase potencies and histamine hH3 receptor affinities

Bioorganic and Medicinal Chemistry

Volumn 11, Issue 10, 2003, Pages 2163-2174

  Graßmann, Sven ^a   Apelt, Joachim ^a   Sippl, Wolfgang ^b   Ligneau, Xavier ^c   Pertz, Heinz H ^a   Zhao, Yuan Hui ^d   Arrang, Jean Michel ^e   Ganellin, C Robin ^d   Schwartz, Jean Charles ^e   Schunack, Walter ^a   Stark, Holger ^f  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

^c Laboratoire Bioprojet   (France)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e CENTRE PAUL BROCA   (France)

^f GOETHE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

1 [4 [5 (1H IMIDAZOL 4 YL)PENTOXY]]PROPIOPHENONE HYDROGEN OXALATE; 2 [3 (1H IMIDAZOL 4 YL)PROPOXY]PYRIDIN 3 AMINE HYDROGEN OXALATE; 3 (1 IMIDAZOL 4 YL)PROPYLPYRIDIN 2 YLHYDROGEN OXALATE; 3 (1 TRIPHENYLMETHYL 1H IMIDAZOL 4 YL)PROPANAMINE; 3 (1H IMIDAZOL 4 YL)PROPYL 3 NITROPYRIDIN 2 YL ETHER; 3 (1H IMIDAZOL 4 YL)PROPYL 5 NITROPYRIDIN 5 YL ETHER HYDROGEN OXALATE; 3 (1H IMIDAZOL 4 YL)PROPYL 5 NITROQUINOLIN 8 YL ETHER HYDROGEN OXALATE; 4 [5 (1H IMIDAZOL 4 YL)PENTOXY]ACETOPHENONE HYDROGEN OXALATE; 5 (1H IMIDAZOL 4 YL)PENT 4 ENYLPHENYL ETHER HYDROGEN OXALATE; 5 (1H IMIDAZOL 4 YL)PENTYLPHENYL ETHER HYDROGEN OXALATE; AMINOQUINOLINE DERIVATIVE; CHEMICAL COMPOUND; ENZYME; ETHER DERIVATIVE; FUB 854; HISTAMINE H3 RECEPTOR; IMIDAZOLE DERIVATIVE; LIGAND; MEPACRINE; N (1,2,3,4 TETRAHYDROACRIDIN 9 YL) 2 (1H IMIDAZOL 4 YL)ETHENAMINE DIHYDROGEN OXALATE; N (1,2,3,4 TETRAHYDROACRIDIN 9 YL) 3 (1H IMIDAZOL 4 YL)PROPANAMINE DIHYDROGEN OXALATE; N (3 NITROPYRIDIN 2 YL) 4 [3 (1H IMIDAZOL 4 YL)PROPOXY]ANILINE HYDROGEN OXALATE; N METHYL 3 (1H IMIDAZOL 4 YL)PROPANAMINE; N METHYL N QUINOLIN 4 YL 3 (1H IMIDAZOL 4 YL)PROPANAMINE DIHYDROGEN OXALATE; N METHYLTRANSFERASE; N QUINOLIN 4 YL 2 (1H IMIDAZOL 4 YL)ETHANAMINE; N QUINOLIN 4 YL 3 (1H IMIDAZOL 4 YL)PROPANAMINE DIHYDROGEN OXALATE; OXALIC ACID; TACRINE; TRANSFERASE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ARTICLE; BINDING AFFINITY; BRAIN CORTEX; DRUG ANTAGONISM; DRUG DESIGN; DRUG INHIBITION; DRUG POTENCY; IC 50; KIDNEY; MOLECULAR MODEL; MOLECULAR WEIGHT; PROTON NUCLEAR MAGNETIC RESONANCE; SYNAPTOSOME;

EID: 0037447913     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0968-0896(03)00120-2     Document Type: Article

References (53)

1. Arrang J.-M., Garbarg M., Schwartz J.-C. Nature (London). 302:1983;832.
2. Schwartz J.-C., Arrang J.-M., Garbarg M., Pollard H., Ruat M. Physiol. Rev. 71:1991;1.
3. Brown R.E., Stevens D.R., Haas H.L. Prog. Neurobiol. 63:2001;637.
4. Beaven, M. A. In Pharmacology of Histamine Receptors; Ganellin, C. R.; Parsons M. E., Eds.; Wright: Bristol, 1982; pp 103-145.
5. Maslinski, C.; Fogel, W. In Handbook of Experimental Pharmacology; Uvnäs, B., Ed.; Springer: Berlin-Heidelberg, 1991; pp 165-189.
6. Schwartz J.-C., Pollard H., Bischoff S., Rehault M.C., Verdiére-Sahuque M. Eur. J. Pharmacol. 16:1971;326.
7. Arrang J.-M., Garbarg M., Lancelot J.-C., Lecomte J.-M., Pollard H., Robba M., Schunack W., Schwartz J.-C. Nature (London). 327:1987;117.
8. Hill S.J., Ganellin C.R., Timmerman H., Schwartz J.-C., Shankley N.P., Young J.M., Schunack W., Levi R., Haas H.L. Pharmacol. Rev. 49:1997;253.
9. Nakamura T., Itadani H., Hidaka Y., Ohta M., Tanaka K. Biochem. Biophys. Res. Commun. 279:2000;615.
10. Lovenberg T.W., Roland B.L., Wilson S.J., Jiang X., Pyati J., Huvar A., Jackson M.R., Erlander M.G. Mol. Pharmacol. 55:1999;1101.
11. Lovenberg T.W., Pyati J., Chang H., Wilson S.J., Erlander M.G. J. Pharmacol. Exp. Ther. 293:2000;771.
12. Chazot P.L., Hann V., Wilson C., Lees G., Thompson C.L. Neuroreport. 12:2001;259.
13. Tardivel-Lacombe J., Rouleau A., Heron A., Morisset S., Pillot C., Cochois V., Schwartz J.-C., Arrang J.-M. Neuroreport. 11:2000;755.
14. Stark H., Sippl W., Ligneau X., Arrang J.-M., Ganellin C.R., Schwartz J.-C., Schunack W. Bioorg. Med. Chem. Lett. 11:2001;951.
15. (a) Arrang J.-M., Garbarg M., Schwartz J.-C. Neuroscience. 15:1985;553.
16. (b) Arrang J.-M., Garbarg M., Schwartz J.-C. Neuroscience. 23:1987;149.
17. Panula P., Kuokkanen K., Relja M., Eriksson K.S., Sallmen T., Rinne J.O., Kalimo H. Soc. Neurosci. Abstr. 21:1995;1977.
18. Morisset S., Traiffort E., Schwartz J.-C. Eur. J. Pharmacol. 315:1996;1.
19. Leurs R., Blandina P., Tedford C., Timmerman H. Trends Pharmacol. Sci. 19:1998;177.
20. (a) Miyazaki S., Imaizumi M., Onodera K. Life Sci. 57:1995;2137.
21. (b) Blandina P., Giorgetti M., Bartolini L., Cecchi M., Timmerman H., Leurs R., Pepu G., Giovannini M.G. Br. J. Pharmacol. 119:1996;16562137
22. (c) Onodera K., Miyazaki S., Imaizumi M., Stark H., Schunack W. Naunyn-Schmiedeberg's Arch. Pharmacol. 357:1998;508.
23. Itoh Y., Oishi R., Adachi N., Saeki K. J. Neurochem. 58:1992;884.
24. Apelt J., Ligneau X., Pertz H.H., Arrang J.-M., Ganellin C.R., Schwartz J.-C., Schunack W., Stark H. J. Med. Chem. 45:2002;1128.
25. Nishibori M., Oishi R., Itoh Y., Saeki K. Jpn. J. Pharmacol. 55:1991;539.
26. Horton J.R., Sawada K., Nishibori M., Zhang X., Cheng X. Structure. 9:2001;837.
27. Morisset S., Traiffort E., Schwartz J.-C. Eur. J. Pharmacol. 315:1996;1.
28. Cumming P., Vincent S.R. Biochem. Biopharmacol. 44:1992;1547.
29. Stark H., Purand K., Ligneau X., Rouleau A., Arrang J.-M., Garbarg M., Schwartz J.-C., Schunack W. J. Med. Chem. 39:1996;1157.
30. Mitsunobu O. Synthesis. 1981;1.
31. Yoshino H., Ueda N., Niijima J., Sugumi H., Kotake Y., Koyanagi N., Yoshimatsu K., Asada M., Watanabe T., Nagasu T., Tsukahara K., Iijima A., Kitoh K. J. Med. Chem. 35:1992;2496.
32. Kelley J.L., Miller C.A., MacLean E.W. J. Med. Chem. 20:1977;721.
33. Surrey A.R., Cutler R.A. J. Am. Chem. Soc. 73:1951;2623.
34. Mechoulam R., Hirshfeld A. Tetrahedron. 23:1967;239.
35. Stark H., Lipp R., Schunack W., Arrang J.-M., Garbarg M., Schwartz J.-C. Arch. Pharm. Pharm. Med. Chem. 324:1991;739.
36. Stark H., Hüls A., Ligneau X., Purand K., Pertz H., Arrang J.-M., Schwartz J.-C., Schunack W. Arch. Pharm. Pharm. Med. Chem. 331:1998;211.
37. Ali S.M., Tedford C.E., Gregory R., Handley M.K., Yates S.L., Hirth W.W., Phillips J.G. J. Med. Chem. 42:1999;903.
38. Stark H., Ligneau X., Arrang J.-M., Schwartz J.-C., Schunack W. Bioorg. Med. Chem. Lett. 8:1998;2011.
39. Ligneau X., Morisset S., Tardivel-Lacombe J., Gbahou F., Ganellin C.R., Stark H., Schunack W., Schwartz J.-C., Arrang J.-M. Br. J. Pharmacol. 131:2000;1247.
40. Garbarg M., Arrang J.-M., Rouleau A., Ligneau X., Trung Tuong M.D., Schwartz J.-C., Ganellin C.R. J. Pharmacol. Exp. Ther. 263:1992;304.
41. GRID, version 20, Molecular Discovery Ltd., Oxford, UK.
42. Bowsher R.R., Verburg K.M., Henry D.P. J. Biol. Chem. 258:1983;12215.
43. Garbarg M., Tuong M.D., Gros C., Schwartz J.-C. Eur. J. Pharmacol. 164:1989;1.
44. Whittaker V.P. Ann. N.Y. Acad. Sci. 137:1966;982.
45. Cheng Y.C., Prussoff W.H. Biochem. Pharmacol. 22:1973;3099.
46. Ligneau X., Garbarg M., Vizuette M.L., Diaz J., Purand K., Stark H., Schunack W., Schwartz J.-C. J. Pharmacol. Exp. Ther. 271:1994;452.
47. Bernstein F.C., Koetzle T.F., Williams G.J.B., Meyer E.F., Brice M.D., Rodgers J.R., Kennard O., Shimanouchi T., Tasumi M.J. Mol. Biol. 112:1997;535.
48. SYBYL 6.6, Tripos Associates Inc., St. Louis, USA.
49. Dunbrack R.L. Jr. Proteins. 37:1999;81.
50. Weiner S.J., Kollman P.A., Nguyen D.T., Case D.A. J. Comput. Chem. 13:1986;230.
51. Morris A.L., MacArthur M.W., Hutchinson E.G., Thornton J.M. Proteins. 12:1992;345.
52. Goodsell D.S., Morris G.M., Olson A.J. J. Mol. Recognit. 9:1996;1.
53. Vedani A., Huhta D.W. J. Am. Chem. Soc. 112:1990;269.